After Hours Summary

Tuesday, April 1, 2008

After Hours Summary: BLUD +4.5 on earnings/guidance; PFE -1.3% (announces discontinuation of Phase III clinical trial for patients with advanced melanoma)

Companies moving in after hours trading in reaction to earnings: Trading Up: EXFO +5.0%; BLUD +4.5%; LORL +2.7%... Companies moving in after hours trading in reaction to news: Trading Up: CPST +3.5% (receives HEV bus order for $5 mln from DesignLine International); AER +2.0% (announced its subsidiary AeroTurbine entered into a ten year component lease agreement signed between British Airways and AeroTurbine); CVTX +1.9% (announces Ranexa significantly reduces cardiac chest pain symptoms and recurrent ischemia in merlin-timi 36 patients with angina); MPG +0.9% (Third Point discloses 7.1% stake in 13D filing); MANT +0.8% (1Q08 contract awards total $750 mln)... Trading Down: LOJN -20.0% (lowers FY08 EPS and revs below consensus; guides Q1 EPS below consensus); ISTA -15.5% (announces results of clinical trial of Xibrom QD formulation; showed no statistically significant difference between the two formulations in achieving the secondary efficacy endpoints); CHRD -14.7% (issues downside Q2 guidance); ONT -7.7% (sees Q4 revs above consensus, EPS in-line; delay of filing annual report pending completion of review); KKD -5.2% (seeks amendments to credit facilities); FIC -4.4% (announces reengineering plan; expects to reduce cost structure by $100 mln, yield annual pre-tax savings of $35 mln and a Q2 charge of $7 mln); BOBE -4.1% (reports March restaurant same store sales +0.1%; co reports Mimi's Cafe March same store sales -4.3%); DEEP -2.9% (notifies SEC of delay in filing its 2007 Q4 and full year results; sees FY07 revs above consensus); HNSN -2.9% (hnsn +2.9% (announces 2.5 mln share offering); ROL -2.2% (announces that it purchased 236K shares of common stock at weighted avg price of $17.09/share in 1Q08); ISSI -1.8% (announces that its Board has elected Scott Howarth as CEO); AVY -1.4% (acquires DM Label Group); DDS -1.4% (reaches settlement agreement with Barington and Clinton); CAL -1.3% (reports March 2008 operational performance); PFE -1.3% (announces discontinuation of Phase III clinical trial for patients with advanced melanoma).

0 comments: